Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and PK of TAK-831 in Healthy Asian Adults
NCT03687684Phase 1Completed
- Sponsor
- Neurocrine Biosciences
- Start
- Oct 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of luvadaxistat in schizophrenia and Friedreich's ataxia (FA), sponsored by Neurocrine Biosciences. Primary endpoints: Number of Participants Reporting at Least One Treatment-emergent Adverse Event at Day 31, Number of Participants Reporting at Least One TEAE Related to Laboratory Test Results at Day 31 and 2 more. Started Oct 2018; status: completed.
02
Drugs
luvadaxistat
03
Conditions
schizophreniaFriedreich's ataxia (FA)
Beyond the preview
Go deeper on NCT03687684.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03687684.